Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada.
It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
The company is also developing etripamil for the indication of atrial fibrillation with rapid ventricular rate (AFib-RVR).
It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil.
Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.
